Clinical Trials

Clinical Trials

#Type of drug / Type of studyName of drug / Name of interventionCompany/InstitutionPatients who may be eligiblePhaseRoute of administration of study drugLocation of trial sitesTrial identifier (Click for more information on clinicaltrials.gov)Email contact addressStudy Website
1mAb CD8+KLRG1+ (Tc)ABC008AbcuroAdults with IBM2/3SC every 8 weeksUSA, INTERNATIONAL (PLANNED)NCT05721573IBM-201_clinicaltrial@abcuro.com
2IST (Te blocker)SirolimusUniversity of Kansas Medical Center, USAAdults with IBM3Oral,once dailyUSA, AUSTRALIANCT04789070aheim2@kumc.edu
3Autologous uncultured adipose-derived stromal vascular fractionADSVFAssistance Publique - Hôpitaux de ParisAdults with IBM1InjectionFRANCENCT05032131olivier.benveniste@aphp.fr
4TYK2 /JAK1 inhibitorBrepocitinib (VALOR)PriovantAdults with DM3Oral,once dailyINTERNATIONALNCT05437263ValorStudyManager@PriovantTx.comhttps://valorstudy.com/
5FcRn inhibitorEfgartigimod PH20 SC (ALKIVIA)ArgenxAdults with IIM (including DM, IMNM, PM, Asys)2/3SC injection weeklyINTERNATIONALNCT05523167ClinicalTrials@argenx.comhttps://myositis.researchstudytrial.com/
6FcRn inhibitorNipocalimab (SPIREA)JanssenAdults with IIM (including DM, IMNM, PM, Asys)2IV biweeklyINTERNATIONALNCT05379634Participate-In-This-Study@its.jnj.comhttps://iimresearchstudy.com/about-the-spirea-study.html
7TLR7/8 inhibitorEmpatoran M5049 (NEPTUNIA)EMD SeronoAdults with DM and PM2Oral,twice dailyINTERNATIONALNCT05650567service@emdgroup.com; eMediUSA@emdserono.com (US only )https://clinicaltrials.merckgroup.com/en/trial-details/?id=MS200569_0041
8TYK2 inhibitorGLPG3667 (GALARISSO)Galapagos NVAdults with DM2Oral,once dailyUSANCT05695950medicalinfo@glpg.com https://www.glpg.com/press-release/3839/galapagos-announces-start-of-phase-2-study-with-selective-tyk2-inhibitor-glpg3667-in-patients-with-dermatomyositis
9SCIGIgPro20 (RECLAIIM)CSL BehringAdults with DM3SC infusion weeklyINTERNATIONALNCT04044690clinicaltrials@cslbehring.com
10C5 inhibitorRavulizumabAlexionAdults with DM2/3IV every 8 weeksINTERNATIONALNCT04999020clinicaltrials@alexion.com
11IFN beta blockerPF-06823859PfizerAdults with DM and PM3IV every 4 weeksINTERNATIONALNCT05895786ClinicalTrials.gov_Inquiries@pfizer.com
12Anti-ILT7HZN-7734 DaxdilimabHorizonAdults with DM and Asys2SC injection weeklyUSA, AUSTRALIANCT05669014ClinicalTrials.gov_Inquiries@pfizer.com
13Boehringer IngelheimNintedanib OfevTYK inhibitorMyositis Associated Interstitial Lund Disease (MA-ILD)4Oral,twice dailyUSANCT05799755wes48@pitt.edu
14Steroids/IVIGPulse Methylprednisolone or IVIGUniversity of Sao PaoloAdults with IIM4IV at disease onsetBRAZILNCT03092180samuel.shinjo@gmail.com
15JAK inhibitorBaricitinib (MYOCIT)Assistance Publique - Hôpitaux de ParisChildren 3-18 years old with new onset JDM2Oral,once dailyFRANCENCT05524311brigitte.bader-meunier@aphp.fr
16n/aClinical Database and Biobank of Patients With Inflammatory Myopathies: the MASC Project (Myositis, DNA, Serum, Cells) (MASC)Groupe Hospitalier Pitie-SalpetriereAll patients who had a confirmed or suspected myositis4n/aFRANCENCT04637672yves.allenbach@aphp.fr
17n/aRheumatoid Arthritis and Myositis CohortAttune Health Research Inc.All patients seen with Rheumatoid Arthritis or Myositis who are at least 18 years of age will be eligible for the study4n/aUSANCT05627089natalie@attunehealth.com
18n/aSporadic Inclusion Body Myositis Natural History Study (INSPIRE-IBM)University of California, Irvine, USAAdults with IBM4n/aUSANCT05046821mwencel@hs.uci.edu
19n/aNatural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory MyopathiesNational Institute of Environmental Health Sciences (NIEHS)Adult- and childhood-onset myositis (2-100 yrs old )4n/aUSANCT00017914 schiffenbauera2@mail.nih.gov; riderl@mail.nih.gov
20n/aNatural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related DiseasesNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Patients 16 years of age and older with polymyositis, dermatomyositis, or a related disorder may be eligible for this study4n/aUSANCT00001265andrew.mammen@nih.gov; julie.thompson@nih.gov
Abbreviations

IBM: Inclusion Body Myositis
DM: Dermatomyositis
JDM: Juvenile Dermatomyositis
PM: Polymyositis
IIM: Idiopathic Inflammatory Myositis
IMNM: Immune-mediated Necrotising Myopathy
Asys: Anti-synthetase-associated Myositis
MA-ILD: Myositis Associated Interstitial Lung Disease